Kisspeptin (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

One subcutaneous injection daily is the cadence throughout the course; kisspeptin is dosed every day and the master sheet lists no off days or washout block between cycles. The two step titration is deliberately conservative so that individual response can be assessed before the dose doubles. At 10 mg/mL every dose in this protocol is a very small draw of 1 to 2 units, which is 0.01 to 0.02 mL, so for administrations of 10 units (0.10 mL) or smaller an insulin syringe marked to 30 or 50 units reads far more accurately than a 100 unit barrel; at this concentration half a unit is 50 mcg. Sites are rotated systematically across abdomen, thighs, and upper arms to reduce local irritation.

Results Timeline

Sequence described in the research record. Individual response varies.

• Weeks 1 to 2: the course opens at 100 mcg daily, which is 1 unit, while tolerance and individual response are assessed.
• Weeks 3 onward: the daily dose steps up to 200 mcg, which is 2 units, and holds there for the remainder of the course.
• Week 8: the shorter course ends here, with 12 weeks as the standard longer option and 16 weeks as the outer bound used for supply planning.
• Throughout: each injection triggers an immediate GnRH release, with LH and FSH secretion following from the anterior pituitary.

Reconstitution Steps

1. Draw 1.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe: 100 mcg = 1 unit, 200 mcg = 2 units.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at minus 20 °C in dry, dark conditions, with desiccant if possible.
• Reconstituted: refrigerate at 2 to 8 °C, protected from light, and use within about 4 weeks; avoid repeated freeze-thaw cycles.

• Allow vials to reach room temperature before opening to reduce condensation uptake.
• Discard bacteriostatic water 28 days after the bottle is first punctured, and date the vial label at reconstitution so the 4 week in-use window is easy to track.

Supplies Needed

Planning is based on an 8 to 16 week daily course with gradual titration, which runs 0.7 mg per week through the 100 mcg opening block and 1.4 mg per week once the dose reaches 200 mcg.

Peptide Vials (Kisspeptin, 10 mg vial):

• An 8 week course totals about 9.8 mg, 12 weeks about 15.4 mg, and 16 weeks about 21.0 mg, which the master sheet plans as roughly 1 vial, 2 vials, and 3 vials of the 10 mg presentation; reconstituted peptide is used within about 4 weeks, so that in-use window, rather than the raw milligrams, is what pushes the longer courses onto the extra vial.

Insulin Syringes (U-100):

• Per week: 7 syringes, one per day (U-100, with 30 or 50 unit markings preferred at these small volumes).
• 8 weeks: 56 syringes. 12 weeks: 84 syringes. 16 weeks: 112 syringes.

Bacteriostatic Water (10 mL bottles):

• Each 10 mg vial takes 1.0 mL, so one 10 mL bottle of bacteriostatic water covers 10 vials, far more than a full 16 week course requires.

Alcohol Swabs:

• Per injection: 2 swabs, one for the vial stopper and one for the site, so 14 swabs per week.
• 8 weeks: 112 swabs (two 100 count boxes). 12 weeks: 168 swabs. 16 weeks: 224 swabs (three 100 count boxes).

Important Notes

Practical considerations for consistency and safety.

• Use a new sterile insulin syringe for each injection and dispose of it in a sharps container.
• Rotate injection sites across abdomen, thighs, and upper arms to reduce local irritation; inject slowly and wait a few seconds before withdrawing the needle.
• Document the daily dose and site rotation to maintain consistency across a course that runs 8 to 16 weeks.
• Discard bacteriostatic water 28 days after opening, and plan vial timing around the roughly 4 week window in which reconstituted peptide is used.
• At 10 mg/mL every dose in this protocol sits between 1 and 2 units, which is 0.01 to 0.02 mL; a 30 unit or 50 unit syringe is the practical choice, since half a unit at this concentration is 50 mcg.
• Regulatory Note: kisspeptin is not an approved drug for human therapeutic use and is supplied for research purposes only, not for human consumption. The master sheet lists no WADA classification for this compound.

How This Works

Kisspeptin is an upstream trigger for the reproductive hormone cascade. After subcutaneous injection it rapidly binds kisspeptin receptors (GPR54) on GnRH neurons in the hypothalamus, causing immediate release of GnRH. That in turn stimulates the anterior pituitary to secrete LH and FSH, which act on the gonads to boost sex steroid production and support gametogenesis. The action is GnRH-dependent: if GnRH release is blocked, kisspeptin cannot induce LH or FSH secretion. This confirms that kisspeptin works by unlocking endogenous GnRH stores, which produces a more physiologic pattern of hormone release than direct GnRH or hCG administration.

Benefits & Side Effects

Observations from the published record.

• Physiological sex hormone stimulation: raises endogenous testosterone and estrogen by amplifying the body's own LH and FSH signals without suppressing the HPG axis.
• Fertility restoration: shows promise in functional hypothalamic amenorrhea by rekindling GnRH and LH pulsatility and resuming menstrual cycles.
• IVF ovulation trigger: can induce a robust LH surge to mature oocytes while potentially lowering the risk of ovarian hyperstimulation syndrome compared with traditional hCG triggers.
• Because the effect depends on existing GnRH stores, the hormone release pattern is closer to physiologic than what direct GnRH or hCG administration produces.
• Safety profile: generally well tolerated in the literature reviewed by the master sheet.
• Possible side effects: occasional mild injection-site reactions such as redness and itch with subcutaneous administration.

Lifestyle Factors

Complementary strategies for best outcomes.

• Adequate nutrition and a healthy body weight support endogenous hormone production, which is what this protocol is meant to amplify.
• Sleep and stress management matter here in particular, since both significantly affect the HPG axis.
• Monitoring changes in reproductive function and hormone-related markers gives the course something objective to be read against.
• In research on hypothalamic suppression, kisspeptin is generally paired with the lifestyle interventions that address the underlying suppression rather than used on its own.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Emerging Therapeutic Potential of Kisspeptin and Neurokinin B (Endocrine Reviews).
2. Kisspeptin-54 triggers egg maturation in IVF with reduced OHSS risk (J Clinical Investigation).
3. Functional hypothalamic amenorrhea: restoration of GnRH pulsatility (Endocrine Reviews).
4. Kisspeptin mechanism: GPR54 receptor binding and GnRH release (Endocrine Reviews).